1. Atomoxetine in comorbid ADHD/PTSD: A randomized, placebo controlled, pilot, and feasibility study
- Author
-
Zhewu Wang, Zachary D. Zuschlag, Ursula S. Myers, and Mark Hamner
- Subjects
Adult ,Cross-Over Studies ,Adrenergic Uptake Inhibitors ,Propylamines ,Atomoxetine Hydrochloride ,Stress Disorders, Post-Traumatic ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,Double-Blind Method ,Attention Deficit Disorder with Hyperactivity ,Quality of Life ,Feasibility Studies ,Humans - Abstract
PTSD and ADHD often occur comorbidly. Research indicates that the cognitive deficits in PTSD may be related to the same disturbance of fronto-temporal systems as observed in ADHD, and ADHD has been shown to impact PTSD treatment outcomes. The presented study evaluated the safety and efficacy of atomoxetine in Veterans with comorbid ADHD/PTSD.A double blind, randomized, placebo controlled, cross-over pilot and feasibility study was conducted. Atomoxetine was examined as an adjunctive treatment over this 10 weeks, two phase, crossover study which compared treatment with atomoxetine 80 mg daily to placebo daily. The primary outcome was improvement in ADHD symptoms as measured by the Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S), the Barkley Adult ADHD Rating Scale-IV (BAARS-IV), and the Adult ADHD Quality of Life-29 (AAQoL-29). Secondary outcomes included the Clinician Administered PTSD Scale (CAPS), Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), and the response inhibition task Go/NoGo (GNG).Atomoxetine treated patients had greater reductions in ADHD symptoms as defined by total scores on the CAARS-S:S (FIn Veterans with ADHD comorbid with PTSD, atomoxetine demonstrated modest efficacy for ADHD symptoms; quality of life measures and PTSD symptoms were not affected.
- Published
- 2022
- Full Text
- View/download PDF